Author

Laura Sayegh

Institution: Thermo Fisher Scientific (Canada)

Observed institution: Thermo Fisher Scientific (Canada)

ORCID: 0009-0001-5751-2643

Observed ORCID: 0009-0001-5751-2643

OpenAlex ID: A5119775820

Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: Multicountry INTEGRATED Observational Study

2024 · Markus Magerl, Laurence Bouillet, et al. · The Journal of Allergy and Clinical Immunology In Practice · 29

Real-world treatment patterns and burden-of-disease of sub-optimally controlled hereditary angioedema

2025 · Henriette Farkas, Emel Aygören-Pürsün, et al. · World Allergy Organization Journal · 7

Predictors of real-world progression-free survival (rwPFS) in patients (pts) with epithelial ovarian cancer (EOC) treated with first-line maintenance (1LM) niraparib (nir): Post hoc analysis of the 1NSPIRE chart review study.

2026 · Lisa Michelle Landrum, Premal H. Thaker, et al. · Journal of Clinical Oncology

Real-world safety profile and clinical management of patients (pts) with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib therapy: Final results from the 1NSPIRE chart review study

2026 · Lisa Landrum, Premal Thaker, et al. · Gynecologic Oncology

Real-world outcomes in patients with epithelial ovarian cancer who received first-line maintenance niraparib: Interim results from the 1NSPIRE chart review study

2025 · Lisa Landrum, Premal Thaker, et al. · Gynecologic Oncology

Works count: 5

Citation count: 36

H-index: 2

I10-index: 1